TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics has appointed Dr. Jason Lickliter as Chief Medical Officer, bringing his extensive experience in oncology and clinical trials to the company. This strategic appointment comes as Amplia advances its clinical trials, notably the ACCENT trial for narmafotinib in pancreatic cancer, and prepares for a new trial in combination with FOLFIRINOX. Dr. Lickliter’s involvement is expected to be pivotal as the company approaches significant data readouts, potentially enhancing its position in the oncology sector and impacting stakeholders positively.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer. FAK is an important target in cancer treatment and also plays a role in chronic diseases like idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: -39.33%
Average Trading Volume: 421,614
Technical Sentiment Signal: Sell
Current Market Cap: A$20.95M
For a thorough assessment of ATX stock, go to TipRanks’ Stock Analysis page.